Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2014

View Archived Issues

Alexar Therapeutics formed to develop LXR agonists

Gilead Sciences discloses new SYK inhibitors

Korean researchers present novel GPR119 receptor agonists for diabetes

The development of an orally available drug-loaded nanoparticle delivery system

First-in-class hKCC2 enhancers for the treatment of neurological diseases

RegeneRx receives orphan drug designation for thymosin beta4

RadioMedix receives orphan drug designation for GalioMedix

Neumedicines joins the Alliance for Biosecurity

Cornerstone Pharmaceuticals presents phase I results for CPI-613 in hematological malignancies

Nang Kuang Pharmaceutical begins phase II trial of ND-420, cisplatin and fluorouracil

Scioderm begins phase IIb study of SD-101 for rare genetic connective tissue disorder

FDA grants orphan drug status to DiaVacs' immunotherapy product for type 1 diabetes

TauRx adds new U.S. centers to clinical trials of investigational treatment for Alzheimer's disease

Mast Therapeutics reports promising data from study using chronic heart failure model

Taisho Pharmaceutical prepares new GlyT1 inhibitors for neurological and other disorders

Japanese group discloses new OX1/OX2 receptor antagonists

Oxygen Biotherapeutics posts protocol for phase III trial of levosimendan in North America

Kala Pharmaceuticals files IND for phase III program for ophthalmic nano-suspension product LE-MPP

Researchers from Curis present preliminary results of a first-in-human trial of CUDC-907

Epizyme reviews recent milestones, looks ahead to 2014

Neurocrine reports data from Kinect 2 study of NBI-98854 in tardive dyskinesia

FDA accepts for filing AEterna Zentaris' NDA for macimorelin acetate for AGHD

NPS Pharmaceuticals receives European orphan drug designation for Natpara

FDA grants fast track designation to Peregrine's immunotherapy bavituximab for second-line NSCLC

Oryzon begins clinical development of its novel LSD1 inhibitor for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...